MDS-O 300mg Tablet
Marketer
Adley Formulations
Salt Composition
Azacitidine (300mg)
Overview MDS-O 300mg Tablet
Azacitidine 300mg tablets are indicated in the management of specific hematological malignancies. They're prescribed for adult patients across all Myelodysplastic Syndrome (MDS) subtypes. Additional uses may be determined by your physician. This medication may be administered with or without food, but consistent daily timing is preferred. Dosage and frequency are physician-determined, based on your condition and may be adjusted. Strict adherence to your doctor's instructions is crucial; improper use or overdose can lead to severe adverse reactions. Therapeutic effects may not be apparent for weeks or months; discontinue use only under your doctor's guidance. Commonly reported side effects include nausea, emesis, asthenia, and pyrexia. Report any concerning symptoms to your physician; management strategies may be available. Vaccination during treatment requires prior physician consultation. Regular monitoring of blood counts, hepatic, renal, and cardiac function is necessary. Prior to commencing treatment, disclose any pre-existing renal or hepatic impairment, or concurrent use of anti-infectives. Potential drug interactions exist; inform your doctor of all medications you are taking. This medication is contraindicated during gestation and lactation.
Uses of MDS-O 300mg Tablet
Myelodysplastic syndromes: Hematological malignancy management
Major Benefits of MDS-O 300mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The 300mg MDS-O Tablet can be administered with or without food, though consistent timing is recommended.
Common Side effects of MDS-O 300mg Tablet:
- Vomiting
- Weakness
- Nausea
- Decreased potassium level in blood
- Bruise
- Fever
- Chills
- Diarrhea
- Constipation
How to use MDS-O 300mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. The tablet should be swallowed whole; do not crush, chew, or break it. MDS-O 300mg Tablets can be ingested with or without food, however, consistent timing is recommended.
How MDS-O 300mg Tablet works:
Leukemia patients receive MDS-O 300mg tablets, an anti-cancer agent. Its mechanism involves disrupting the cancerous cells' DNA and RNA synthesis, thereby inducing cell death and promoting healthy blood cell development within the bone marrow.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside MDS-O 300mg Tablet is not established as safe. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using MDS-O 300mg tablets during pregnancy poses a confirmed risk to the fetus and is therefore inadvisable. Nevertheless, in exceptional circumstances involving life-threatening conditions, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingUNSAFE
Lactation is contraindicated with 300mg MDS-O tablets due to potential infant toxicity. Studies indicate the medication may harm breastfeeding infants.
DrivingUNSAFE
Taking a 300mg MDS-O tablet might lead to adverse reactions, potentially impairing driving ability. Fatigue is one such possible side effect that could compromise safe driving.
KidneyCAUTION
Individuals with kidney impairment should use MDS-O 300mg tablets cautiously. Dosage modification of MDS-O 300mg tablets may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should exercise caution when using MDS-O 300mg tablets, potentially requiring dosage modification. Physician consultation is advised. The use of MDS-O 300mg tablets is contraindicated in individuals with advanced hepatocellular carcinoma.
What if you forget to take MDS-O 300mg Tablet :
NA
Facts to Know About MDS-O 300mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine Nucleoside Analog |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavioral Class | Metabolic Antagonists |
3,018 People bought this recently